Caliper Life Sciences Inc. modifies its $25 million revolving credit line with Silicon Valley Bank, extending the due date into 2011.
Caliper Life Sciences Inc. (NSDQ:CALP) modified its $25 million credit line with Silicon Valley Bank, extending its deadline from Nov. 30, 2010 to April 1, 2011.
The Hopkinton, Mass.-based lab equipment and services provider said the agreement allows for it to borrow up to $25 million in revolving loan advances, according to a regulatory filing, including up to $5 million in letters of credit. If Caliper borrows more than $20 million, the interest rate on the loan is set at a floating annual rate equal to the prime rate plus 1 percent; if it borrows less than $20 million the rate is prime plus two.
Thermo Fisher Scientific Inc. plans to shell out $587 million buying back most of its 2.5 percent convertible senior notes, as it looks to refinance debt its carrying from the 2006 merger of Thermo Electron and Fisher Scientific.
Thermo Fisher Scientific Inc. (NYSE:TMO) plans to spend $586.6 million to refinance a portion of the debt its carrying from before the 2006 merger between Thermo Electron Corp. and Fisher Scientific International Inc.
The Waltham, Mass.-based lab equipment and services firm said it will buy back $282.3 million worth of principal, or about 95.6 percent of the notes, for $2,072.47 per $1,000 of debt. The total nut comes to about $586.6 million, including accrued and unpaid interest.
Abiomed Inc. is touting another study showing the effectiveness of its Impella 2.5 heart pump in high-risk percutaneous coronary interventions.
Abiomed Inc. (NSDQ:ABMD) is touting the results of a new, European study showing the effectiveness of its Impella 2.5 circulatory assist device in high-risk percutaneous coronary intervention procedures.
The Danvers, Mass.-based cardiac assist device maker said the study, "Supported High-Risk Percutaneous Coronary Intervention Using the Impella 2.5 device: The Europella Registry," was published in the Dec. 15 issue of the Journal of the American College of Cardiology. It concludes that "this large multicenter registry supports the safety, feasibility and potential usefulness of hemodynamic support with Impella 2.5 in high-risk PCI."
The Advanced Medical Technology Assn. is starting a new division to lobby for the diagnostics industry in Washington.
The Advanced Medical Technology Assn. (AdvaMed) launched a new lobby for the diagnostics industry it's calling AdvaMed Dx.
The national trade council for the medical device industry said its new division will focus on "issues facing companies that manufacture in vitro diagnostic technologies," functioning as "an association within an association" with access to AdvaMed's resources, according to a press release.
AdvaMed Dx will be governed by an 18-member board of directors, chaired by Beckman Coulter chairman, president and CEO Scott Garrett, and an eight-member executive committee of CEOs from in vitro diagnostics companies.
Interleukin Genetics Inc. launched a genetic test designed to identify people who could be prone to developing osteoporosis.
Interleukin Genetics Inc. (NYSE:ILI) launched a diagnostic test designed to detect genetic patterns associated with osteoporosis.
The Waltham, Mass.-based genetic test developer said its Bone Health Genetic Test, made by its Inherent Health subsidiary, determines a patient's risk for developing vertebral fractures and low bone mineral density.
Deerfield Capital continues to reap the rewards of its investment in NxStage Medical Inc., pulling in $2.7 million in December alone.
NxStage Medical Inc. (NSDQ:NXTM) continues to reward Deerfield Capital, as the New York-based moved to lock in profits by selling a portion of its stake in the home hemodialysis company.
The open-market transactions, completed between Dec. 3 and Dec. 15, generated more than $2.7 million in gross proceeds. The stock fetched an average of about $7.49 a share, or about three times its price as of late March, when Deerfield was snapping up NxStage shares by the armful.
National Dentex Corp. is promoting from within, tapping CEO David Brown as chairman and lifting Josh Green to COO.
Green will eventually become the new Brown at National Dentex Corp. (NSDQ:NADX), as part of the company's transition and succession plan announced Wednesday.
The Natick, Mass.-based crown, bridge and other dental reconstructive tools maker is adding chairman to CEO David Brown's responsibilities, while grooming Josh Green to be his eventual successor, according to a securities filing.
